Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2024 Sep;31(9):e16372.
doi: 10.1111/ene.16372. Epub 2024 Jun 5.

Comparative effectiveness and tolerability of calcitonin gene-related peptide (CGRP) monoclonal antibodies and onabotulinumtoxinA in chronic migraine: A multicenter, real-world study in Taiwan

Yen-Feng Wang  1   2   3 , Fu-Chi Yang  4   5 , Lu-An Chen  6 , Ting-Yu Chang  7   8 , Hui-Chen Su  9   10 , Chun-Pai Yang  11   12 , Yi-Hsien Tu  13 , Yi-Shiang Tzeng  1 , Shih-Pin Chen  1   2   3   14 , Jong-Ling Fuh  1   2   3 , Kuan-Lin Lai  1   2   3 , Yu-Hsiang Ling  1   2 , Wei-Ta Chen  1   2   3   15 , Shuu-Jiun Wang  1   2   3   16
Affiliations
Comparative Study

Comparative effectiveness and tolerability of calcitonin gene-related peptide (CGRP) monoclonal antibodies and onabotulinumtoxinA in chronic migraine: A multicenter, real-world study in Taiwan

Yen-Feng Wang et al. Eur J Neurol. 2024 Sep.

Abstract

Objective: To compare the real-world effectiveness and tolerability of calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) and onabotulinumtoxinA in chronic migraine (CM) patients.

Methods: This multicenter study involved retrospective analysis of prospectively collected data of CM patients treated with CGRP mAbs or onabotulinumtoxinA, including difficult-to-treat (DTT) patients (i.e., ≥3 preventive failures). Treatment outcomes were determined at 6 months based on prospective headache diaries and Migraine Disability Assessment (MIDAS).

Results: The study included 316 (55 M/261F, mean age 44.4 ± 13.5 years) and 333 (61 M/272F, mean age 47.9 ± 13.4 years) CM patients treated with CGRP mAbs or onabotulinbumtoxinA, respectively. At 6 months, CGRP mAb treatment was associated with a greater decrease in monthly migraine days (MMDs) (-13.0 vs. -8.7 days/month, p < 0.001) and a higher ≥50% responder rate (RR) (74.7% vs. 50.7%, p < 0.001) compared with onabotulinumtoxinA injections. The findings were consistent in DTT patients (-13.0 vs. -9.1 MMDs, p < 0.001; ≥50% RR: 73.9% vs. 50.3%, p < 0.001) or those with medication-overuse headache (MOH) (-13.3 vs. -9.0 MMDs, p < 0.001; ≥50% RR: 79.0% vs. 51.6%, p < 0.001). Besides, patients receiving CGRP mAbs had greater improvement (-42.2 vs. -11.8, p < 0.001) and a higher ≥50% RR (62.0% vs. 40.0%, p = 0.001) in MIDAS scores and a lower rate of adverse events (AEs) (6.0% vs. 21.0%, p < 0.001). However, none of the patients discontinued treatment due to AEs.

Conclusions: In this multicenter, real-world study, CGRP mAbs were more effective than onabotulinumtoxinA in CM patients, even in DTT or MOH patients. All of these injectables were well tolerated. Further prospective studies are needed to verify these findings.

Keywords: CGRP; chronic migraine; fremanezumab; galcanezumab; onabotulinumtoxinA; outcome; refractory.

PubMed Disclaimer

Conflict of interest statement

Y.F.W. has received personal fees as an advisor or a speaker from Allergan/AbbVie, Boehringer Ingelheim, Chugai, Eli Lilly, Hava Bio‐Pharma, Lundbeck, Novartis, Orient EuroPharma, Pfizer, Sanofi, Teva, UCB, and Viatris. He has received research grants from the Taiwan National Science and Technology Council, and Taipei Veterans General Hospital. W.T.C. has received honoraria as a speaker from Allergan/AbbVie, Hava Bio‐Pharma, Orient EuroPharma Pfizer, and Viatris. He has received research grants from the Taiwan National Science and Technology Council, and Taipei Veterans General Hospital. S.J.W. has received personal fees as an advisor or speaker from AbbVie, Orient EuroPharma, Pfizer, and Percept; and has been the PI in trials sponsored by Allergan/AbbVie, Lundbeck, Novartis, and Orient EuroPharma. He has received research grants from the Taiwan National Science and Technology Council and Taipei Veterans General Hospital. F.C.Y., L.A.C., T.Y.C., H.C.S., C.P.Y., Y.H.T., Y.S.T., S.P.C., J.L.F., K.L.L., and Y.H.L. report no relevant conflict of interest.

Figures

FIGURE 1
FIGURE 1
Patient selection. CGRP, calcitonin gene‐related peptide; CM, chronic migraine; mAb, monoclonal antibody; OnabotA, onabotulinumtoxinA.
FIGURE 2
FIGURE 2
Treatment outcomes of chronic migraine patients treated with calcitonin gene‐related peptide monoclonal antibodies or onabotulinumtoxinA at 6 months. Least‐squares mean change (standard error) from baseline in the number of monthly migraine days (MMDs) (a) and monthly moderate‐to‐severe migraine days (MMSMDs) (b) and proportions of patients with ≥50% (c) or ≥ 75% (d) reduction in MMDs and MMSMDs at 6 months. CGRP, calcitonin gene‐related peptide; DTT, difficult‐to‐treat; mAb, monoclonal antibody; MMD, monthly migraine day; MMSMD, monthly moderate‐to‐severe migraine day; MOH, medication‐overuse headache; onabotA, onabotulinumtoxinA. ***p ≤ 0.001, **p ≤ 0.01.
FIGURE 3
FIGURE 3
Subgroup analysis in difficult‐to‐treat (DTT) and medication‐overuse headache (MOH) patients. Least‐squares mean change (standard error) from baseline in the number of monthly migraine days (MMDs) (a) at 6 months and ≥ 50% and ≥ 75% responder rates for MMDs (b) in patients who were DTT and those with MOH (c, d). CGRP, calcitonin gene‐related peptide; DTT, difficult‐to‐treat; mAb, monoclonal antibody; MMD, monthly migraine day; MOH, medication‐overuse headache; onabotA, onabotulinumtoxinA. ***p ≤ 0.001, **p ≤ 0.01, *p < 0.05.
FIGURE 4
FIGURE 4
Patient‐reported outcomes in chronic migraine patients. (a) Least‐squares mean change from baseline in Migraine Disability Assessment (MIDAS) score, (b) proportions of patients with ≥50% and ≥ 75% response, and (c) patient's subjective ratings on overall effectiveness. ***p ≤ 0.001, ** p ≤ 0.01.
See this image and copyright information in PMC

References

    1. May A, Schulte LH. Chronic migraine: risk factors, mechanisms and treatment. Nat Rev Neurol. 2016;12:455‐464. - PubMed
    1. Lipton RB, Manack Adams A, Buse DC, Fanning KM, Reed ML. A comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) study and American Migraine Prevalence and Prevention (AMPP) study: demographics and headache‐related disability. Headache. 2016;56:1280‐1289. - PMC - PubMed
    1. Chen PK, Wang SJ. Medication overuse and medication overuse headache: risk factors, comorbidities, associated burdens and nonpharmacologic and pharmacologic treatment approaches. Curr Pain Headache Rep. 2019;23:60. - PubMed
    1. Buse DC, Rains JC, Pavlovic JM, et al. Sleep disorders among people with migraine: results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study. Headache. 2019;59:32‐45. - PMC - PubMed
    1. Lipton RB, Seng EK, Chu MK, et al. The effect of psychiatric comorbidities on headache‐related disability in migraine: results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study. Headache. 2020;60:1683‐1696. - PMC - PubMed

MeSH terms

Substances